- Home
- AGIO vs LILAK Comparison
AGIO vs LILAK Comparison
Compare AGIO & LILAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGIO | LILAK |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | United States | Bermuda |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Cable & Other Pay Television Services |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2013 | 2017 |
Fundamental Metrics
Financial Performance| Metric | AGIO | LILAK |
|---|---|---|
| Price | $33.62 | $8.71 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 1 |
| Target Price | ★ $38.88 | $8.20 |
| AVG Volume (30 Days) | 777.0K | ★ 1.2M |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.55 |
| EPS | N/A | ★ N/A |
| Revenue | $43,011,000.00 | ★ $4,442,200,000.00 |
| Revenue This Year | $76.75 | $1.37 |
| Revenue Next Year | $170.73 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $22.24 | $4.75 |
| 52 Week High | $46.00 | $9.13 |
Technical Indicators
Market Signals| Indicator | AGIO | LILAK |
|---|---|---|
| Relative Strength Index (RSI) | 48.19 | 59.29 |
| Support Level | $32.54 | $7.38 |
| Resistance Level | $36.04 | $8.93 |
| Average True Range (ATR) | 1.28 | 0.25 |
| MACD | 0.10 | -0.01 |
| Stochastic Oscillator | 42.77 | 94.59 |
Price Performance
Historical ComparisonAbout AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
About LILAK Liberty Latin America Ltd. Class C
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.